Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma

Jacob J Adashek; Meghan M Salgia; Edwin M Posadas; Robert A Figlin; Jun Gong

doi:10.1016/j.clgc.2019.01.004

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma

Clin Genitourin Cancer. 2019 Jun;17(3):e454-e460. doi: 10.1016/j.clgc.2019.01.004. Epub 2019 Jan 15.

Authors

Jacob J Adashek¹, Meghan M Salgia², Edwin M Posadas³, Robert A Figlin³, Jun Gong⁴

Affiliations

¹ Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, Pomona, CA.
² Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA.
³ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
⁴ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: [email protected].

PMID: 30733185
DOI: 10.1016/j.clgc.2019.01.004

Abstract

Renal-cell carcinoma remains one of the elusive cancers that lacks a biomarker. It is the eighth most commonly diagnosed malignancy in the United States, and the incidence has slowly trended upward. In addition to the increase in newly diagnosed cases, the prevalence and overall survival of individuals with kidney cancer also has increased substantially. This formal review synopsizes the literature regarding the current treatment landscape, the utility of biomarkers in renal-cell carcinoma, and future directions regarding next-generation sequencing of circulating tumor DNA.

Keywords: IOs; VEGF; VHL; ctDNA; mTOR.

Publication types

Review

MeSH terms

Biomarkers, Tumor / genetics*
Carcinoma, Renal Cell / genetics
Carcinoma, Renal Cell / secondary*
Carcinoma, Renal Cell / therapy
Circulating Tumor DNA / analysis*
Combined Modality Therapy
Humans
Kidney Neoplasms / genetics
Kidney Neoplasms / pathology*
Kidney Neoplasms / therapy
Prognosis

Substances

Biomarkers, Tumor
Circulating Tumor DNA